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These guidelines are intended for use by infectious disease specialists, orthopedists, and other healthcare
professionals who care for patients with prosthetic joint infection (PJI). They include evidence-based and
opinion-based recommendations for the diagnosis and management of patients with PJI treated with
debridement and retention of the prosthesis, resection arthroplasty with or without subsequent staged
reimplantation, 1-stage reimplantation, and amputation.
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EXECUTIVE SUMMARY
Background
Joint replacement is a highly effective intervention
that signiﬁcantly improves patients’ quality of life, pro-
viding symptom relief, restoration of joint function,
improved mobility, and independence. Prosthetic joint
infection (PJI) remains one of the most serious com-
plications of prosthetic joint implantation. The man-
agement of PJI almost always necessitates the need for
surgical intervention and prolonged courses of intrave-
nous or oral antimicrobial therapy [1–4]. Despite a
signiﬁcant amount of basic and clinical research in
this ﬁeld, many questions pertaining to the deﬁnition
of infection as well as diagnosis and management of
these infections remain unanswered. The focus of
these guidelines is to provide a consensus statement
that addresses the diagnosis and the medical and sur-
gical treatment of infections involving a prosthetic
joint. In many situations, the panel has made recom-
mendations based on expert opinion, realizing that the
amount of data to support a speciﬁc recommendation
is limited and that there are diverse practice patterns
which seem to be equally effective for a given clinical
problem.
An essential component of the care of patients with
PJI is strong collaboration between all involved medical
and surgical specialists (eg, orthopedic surgeons, plastic
surgeons, infectious disease specialists, internists). It is
anticipated that consideration of these guidelines may
help reduce morbidity, mortality, and the costs associat-
ed with PJI. The panel realizes that not all medical
institutions will have the necessary resources to
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implement all the recommendations in these guidelines. Proper
referral to specialty centers may need to occur.
Each section of the guideline begins with a speciﬁc clinical
question and is followed by numbered recommendations and
a summary of the most relevant evidence in support of the
recommendations. The panel followed a process used in the
development of other Infectious Diseases Society of America
(IDSA) guidelines, which included a systematic weighting of
the quality of the evidence and the grade of recommendation [5]
(Table 1). A detailed description of the methods, background,
and evidence summaries that support each of the recommen-
dations can be found in the full text of the guideline. Areas of
controversy in which data are limited or conﬂicting and where
additional research is needed are indicated throughout the
document and are highlighted in the “Research Gaps” section
in the full text of the guideline.
I. What preoperative evaluation and intraoperative testing
should be performed to diagnose PJI and what is the deﬁnition
of PJI?
Recommendations
Preoperative Evaluation (Figure 1)
1. Suspect PJI in patients with any of the following (B-III):
A sinus tract or persistent wound drainage over a joint pros-
thesis, acute onset of a painful prosthesis, or any chronic
painful prosthesis at any time after prosthesis implantation,
particularly in the absence of a pain-free interval, in the ﬁrst
few years following implantation or if there is a history of
prior wound healing problems or superﬁcial or deep infection.
2. Evaluation of the patient with a possible PJI should
include a thorough history and physical examination (C-III).
Items that should be obtained in the history include the type
of prosthesis, date of implantation, past surgeries on the joint,
history of wound healing problems following prosthesis im-
plantation, remote infections, current clinical symptoms, drug
allergies and intolerances, comorbid conditions, prior and
current microbiology results from aspirations and surgeries,
and antimicrobial therapy for the PJI including local antimi-
crobial therapy (C-III).
3. A test for sedimentation rate or C-reactive protein (CRP)
should be performed in all patients with a suspected PJI when
the diagnosis is not clinically evident. The combination of an
abnormal sedimentation rate and CRP seems to provide the
best combination of sensitivity and speciﬁcity (A-III).
4. A plain radiograph should be performed in all patients
with suspected PJI (A-III).
5. A diagnostic arthrocentesis should be performed in all pa-
tients with suspected acute PJI unless the diagnosis is evident
clinically and surgery is planned and antimicrobials can be safely
withheld prior to surgery. Arthrocentesis is also advised in pa-
tients with a chronic painful prosthesis in whom there is an un-
explained elevated sedimentation rate or CRP level (A-III) or in
whom there is a clinical suspicion of PJI. It may not be necessary
if in this situation surgery is planned and the result is not expect-
ed to alter management. Synovial ﬂuid analysis should include a
total cell count and differential leukocyte count, as well as
culture for aerobic and anaerobic organisms (A-III). A crystal
analysis can also be performed if clinically indicated.
6. In PJI where the patient is medically stable, withholding
antimicrobial therapy for at least 2 weeks prior to collection of
synovial ﬂuid for culture increases the likelihood of recovering
an organism (B-III).
7. Blood cultures for aerobic and anaerobic organisms
should be obtained if fever is present, there is an acute onset
of symptoms, or if the patient has a condition or suspected
condition or concomitant infection or pathogen (eg Staphylo-
coccus aureus) that would make the presence of a bloodstream
infection more likely (B-III).
8. Imaging studies such as bone scans, leukocyte scans,
magnetic resonance imaging, computed tomography, and pos-
itron emission tomography scans should not be routinely used
to diagnose PJI (B-III).
Intraoperative Diagnosis of PJI
9. Intraoperative histopathological examination of peripros-
thetic tissue samples is a highly reliable diagnostic test provid-
ed that a pathologist skilled in interpretation of periprosthetic
tissue is available. It should be performed at the time of revi-
sion prosthetic joint surgery, when available, if the presence of
infection is in doubt based on the clinical suspicion of the
Table 1. Strength of Recommendation and Quality of Evidence
Category/Grade Definition
Strength of recommendation
A Good evidence to support a recommendation
for or against use.
B Moderate evidence to support a
recommendation for or against use.
C Poor evidence to support a recommendation.
Quality of evidence
I Evidence from >1 properly randomized,
controlled trial.
II Evidence from >1 well-designed clinical trial,
without randomization; from cohort or
case-controlled analytic studies (preferably
from >1 center); from multiple time-series; or
from dramatic results from uncontrolled
experiments.
III Evidence from opinions of respected
authorities, based on clinical experience,
descriptive studies, or reports of expert
committees.
Source: [5]. Adapted and reproduced with the permission of the Minister of
Public Works and Government Services Canada, 2009.
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surgeon and the results will affect management, for example,
in deciding between revision arthroplasty and 2-stage
exchange (B-III).
10. At least 3 and optimally 5 or 6 periprosthetic intra-
operative tissue samples or the explanted prosthesis itself
should be submitted for aerobic and anaerobic culture at
Figure 1. Preoperative and intraoperative diagnosis of prosthetic joint infection. Abbrevation: CRP, C-reactive protein.
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the time of surgical debridement or prosthesis removal to
maximize the chance of obtaining a microbiologic diagnosis
(B-II).
11. When possible (see above), withholding antimicrobial
therapy for at least 2 weeks prior to collecting intraoperative
culture specimens increases the yield of recovering an organ-
ism (A-II).
Deﬁnition of PJI
12. The presence of a sinus tract that communicates with
the prosthesis is deﬁnitive evidence of PJI (B-III).
13. The presence of acute inﬂammation as seen on histo-
pathologic examination of periprosthetic tissue at the time of
surgical debridement or prosthesis removal as deﬁned by
the attending pathologist is highly suggestive evidence of PJI
(B-II).
14. The presence of purulence without another known eti-
ology surrounding the prosthesis is deﬁnitive evidence of PJI
(B-III).
15. Two or more intraoperative cultures or combination of
preoperative aspiration and intraoperative cultures that yield
the same organism (indistinguishable based on common labo-
ratory tests including genus and species identiﬁcation or
common antibiogram) may be considered deﬁnitive evidence
of PJI. Growth of a virulent microorganism (eg, S. aureus) in
a single specimen of a tissue biopsy or synovial ﬂuid may
also represent PJI. One of multiple tissue cultures or a single
aspiration culture that yields an organism that is a common
contaminant (eg, coagulase-negative staphylococci, Propioni-
bacterium acnes) should not necessarily be considered evi-
dence of deﬁnite PJI and should be evaluated in the context of
other available evidence (B-III).
16. The presence of PJI is possible even if the above criteria
are not met; the clinician should use his/her clinical judgment
to determine if this is the case after reviewing all the available
preoperative and intraoperative information (B-III).
II. What different surgical strategies should be considered for
treatment of a patient with PJI?
Recommendations
17. The ultimate decision regarding surgical management
should be made by the orthopedic surgeon with appropriate
consultation (eg, infectious diseases, plastic surgery) as neces-
sary (C-III).
18. Patients diagnosed with a PJI who have a well-ﬁxed
prosthesis without a sinus tract who are within approximately
30 days of prosthesis implantation or <3 weeks of onset of
infectious symptoms should be considered for a debridement
and retention of prosthesis strategy (Figure 2; A-II). Patients
who do not meet these criteria but for whom alternative surgi-
cal strategies are unacceptable or high risk may also be
considered for a debridement and retention strategy, but
relapse of infection is more likely (B-III).
19. A 2-stage exchange strategy is commonly used in the
United States and is indicated in patients who are not candi-
dates for a 1-stage exchange who are medically able to
undergo multiple surgeries and in whom the surgeon believes
reimplantation arthroplasty is possible, based on the existing
soft tissue and bone defects (Figure 3; B-III). Obtaining a pre-
revision sedimentation rate and CRP is recommended by the
panel to assess the success of treatment prior to reimplanta-
tion (C-III). The panel believes that in selected circumstances
more than one 2-stage exchange if the ﬁrst attempt fails can
be successful (C-III).
20. A 1-stage or direct exchange strategy for the treatment of
PJI is not commonly performed in the United States but may be
considered in patients with a total hip arthroplasty (THA) infec-
tion who have a good soft tissue envelope provided that the
identity of the pathogens is known preoperatively and they are
susceptible to oral antimicrobials with excellent oral bioavailabil-
ity. There may be a greater risk of failure if bone grafting is
required and effective antibiotic impregnated bone cement
cannot be utilized (Figure 3; C-III).
21. Permanent resection arthroplasty may be considered
in nonambulatory patients; patients with limited bone stock,
poor soft tissue coverage, or infections due to highly resis-
tant organisms for which there is limited medical therapy;
patients with a medical condition precluding multiple major
surgeries; or patients who have failed a previous 2- stage
exchange in which the risk of recurrent infection after
another staged exchange is deemed unacceptable (Figure 4;
B-III).
22. Amputation should be the last option considered but
may be appropriate in selected cases. Except in emergent
cases, referral to a center with specialist experience in the
management of PJI is advised before amputation is carried
out (Figure 4; B-III).
III. What is the medical treatment for a patient with PJI
following debridement and retention of the prosthesis?
Recommendations
Staphylococcal PJI
23. Two to 6 weeks of a pathogen-speciﬁc intravenous anti-
microbial therapy (Table 2) in combination with rifampin
300–450 mg orally twice daily followed by rifampin plus a
companion oral drug for a total of 3 months for a THA infec-
tion and 6 months for a total knee arthroplasty (TKA) infec-
tion (A-I). Total elbow, total shoulder, and total ankle
infections may be managed with the same protocols as THA
infections (C-III). Recommended oral companion drugs for
rifampin include ciproﬂoxacin (A-I) or levoﬂoxacin (A-II).
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Secondary companion drugs to be used if in vitro susceptibil-
ity, allergies, intolerances, or potential intolerances support
the use of an agent other than a quinolone include but are not
limited to co-trimoxazole (A-II), minocycline or doxycycline
(C-III), or oral ﬁrst-generation cephalosporins (eg, cephalex-
in) or antistaphylococcal penicillins (eg, dicloxacillin; C-III).
If rifampin cannot be used because of allergy, toxicity, or
intolerance, the panel recommends 4–6 weeks of pathogen-
speciﬁc intravenous antimicrobial therapy (B-III).
24. Monitoring of outpatient intravenous antimicrobial
therapy should follow published guidelines (A-II) [6].
25. Indeﬁnite chronic oral antimicrobial suppression may
follow the above regimen with cephalexin, dicloxacillin, co-
trimoxazole, or minocycline based on in vitro susceptibility,
allergies, or intolerances (Table 3; B-III). Rifampin alone is
not recommended for chronic suppression, and rifampin com-
bination therapy is not generally recommended. One member
of the panel uses rifampin combination therapy for chronic
suppression in selected situations (A. R. B.). The recommen-
dation regarding using suppressive therapy after rifampin
treatment was not unanimous (W. Z., D. L.). Clinical and lab-
oratory monitoring for efﬁcacy and toxicity is advisable. The
decision to offer chronic suppressive therapy must take into
account the individual circumstances of the patient including
the ability to use rifampin in the initial phase of treatment,
the potential for progressive implant loosening and loss of
bone stock, and the hazards of prolonged antibiotic therapy; it
is therefore generally reserved for patients who are unsuitable
for, or refuse, further exchange revision, excision arthroplasty,
or amputation.
Figure 2. Management of prosthetic joint infection.
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PJI Due to Other Organisms
26. Four to 6 weeks of pathogen-speciﬁc intravenous or
highly bioavailable oral antimicrobial therapy (Table 2; B-II).
27. Monitoring of outpatient intravenous antimicrobial
therapy should follow published guidelines (A-II) [6].
28. Indeﬁnite chronic oral antimicrobial suppression may
follow the above regimens (Table 3) based on in vitro sensitiv-
ities, allergies, and intolerances (B-III). Chronic suppression
after ﬂuoroquinolone treatment of PJI due to gram-negative
bacilli was not unanimously recommended (W. Z., D. L.).
Clinical and laboratory monitoring for efﬁcacy and toxicity is
advisable. Similar considerations regarding hazards and effec-
tiveness apply to those above.
IV. What is the medical treatment for a patient with PJI
following resection arthroplasty with or without planned staged
reimplantation?
Recommendations
29. Four to 6 weeks of pathogen-speciﬁc intravenous or
highly bioavailable oral antimicrobial therapy is recommended
(Table 2; A-II).
30. Monitoring of outpatient intravenous antimicrobial
therapy should follow published guidelines (A-II) [6].
V. What is the medical treatment for a patient with PJI
following 1-stage exchange?
Recommendations
Staphylococcal PJI
31. Two to 6 weeks of pathogen-speciﬁc intravenous anti-
microbial therapy in combination with rifampin 300–450 mg
orally twice daily followed by rifampin plus a companion oral
drug for a total of 3 months is recommended (Table 2; C-III).
Recommended oral companion drugs for rifampin include
ciproﬂoxacin (A-I) or levoﬂoxacin (A-II). Secondary compan-
ion drugs to be used if in vitro susceptibility, allergies, intoler-
ances, or potential intolerances support the use of an agent
other than a quinolone include but are not limited to co-tri-
moxazole (A-II), minocycline or doxycycline (B-III), or oral
ﬁrst-generation cephalosporins (eg, cephalexin) or antistaphy-
lococcal penicillins (eg, dicloxacillin; C-III). If rifampin
cannot be used because of allergy, toxicity, or intolerance,
than the panel recommends 4–6 weeks of pathogen-speciﬁc
intravenous antimicrobial therapy.
32. Monitoring of outpatient intravenous antimicrobial
therapy should follow published guidelines (A-II) [6].
33. Indeﬁnite chronic oral antimicrobial suppression may
follow the above regimen with either cephalexin, dicloxacillin,
co-trimoxazole, or minocycline or doxycycline based on in
vitro susceptibility, allergies, or intolerances (Table 3; B-III).
Rifampin alone is not recommended for chronic suppression,
and rifampin combination therapy is also not generally rec-
ommended. One member of the panel uses rifampin combina-
tion therapy for chronic suppression in selected situations
(A. R. B.). The recommendation regarding using suppressive
therapy after rifampin treatment was not unanimous (D. L.,
W. Z.). Clinical and laboratory monitoring for efﬁcacy and
toxicity is advisable. The decision to offer chronic suppressive
therapy must take into account the individual circumstances
of the patient including the ability to use rifampin in the
initial phase of treatment, the potential for progressive
Figure 3. Management of prosthetic joint infection—removal of prosthesis. Abbreviation: THA, total hip arthroplasty.
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implant loosening and loss of bone stock, and the hazards of
prolonged antibiotic therapy; it is therefore generally reserved
for patients who are unsuitable for, or refuse, further exchange
revision, excision arthroplasty, or amputation.
PJI Due to Other Organisms
34. Four to 6 weeks of pathogen-speciﬁc intravenous or
highly bioavailable oral antimicrobial therapy is recommended
(Table 2; A-II).
35. Monitoring of outpatient intravenous antimicrobial
therapy should follow published guidelines (A-II) [6].
36. Indeﬁnite chronic oral antimicrobial suppression
should follow regimens in Table 3 and be based on in vitro
sensitivities, allergies, and intolerances (B-III). Chronic sup-
pression after ﬂuoroquinolone treatment of gram-negative
bacilli was not unanimously recommended (D. L., W. Z.).
Clinical and laboratory monitoring for efﬁcacy and toxicity
is advisable. Similar considerations regarding hazards and
effectiveness apply to those above.
VI. What is the medical treatment for a patient with PJI
following amputation?
37. Pathogen-speciﬁc antimicrobial therapy should be given
until 24–48 hours after amputation assuming all infected bone
and soft tissue has been surgically removed and there is no
concomitant sepsis syndrome or bacteremia. If sepsis syn-
drome or bacteremia are present, treatment duration is to be
according to recommendations for these syndromes (C-III).
Figure 4. Management of prosthetic joint infection when patients are not a candidate for new prosthesis. Abbreviations: TEA, total elbow arthro-
plasty; TKA, total knee arthroplasty.
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Table 2. Intravenous or Highly Bioavailable Oral Antimicrobial Treatment of Common Microorganisms Causing Prosthetic Joint Infection (B-III Unless Otherwise Stated in Text)
Microorganism Preferred Treatmenta Alternative Treatmenta Comments
Staphylococci, oxacillin-
susceptible
Nafcillinb sodium 1.5–2 g IV q4-6 h Vancomycin IV 15 mg/kg q12 h See recommended use of rifampin as a
companion drug for rifampin-susceptible
PJI treated with debridement and
retention or 1-stage exchange in text
or or
Cefazolin 1–2 g IV q8 h Daptomycin 6 mg/kg IV q 24 h
or or
Ceftriaxonec 1–2 g IV q24 h Linezolid 600 mg PO/IV every 12 h
Staphylococci, oxacillin-
resistant
Vancomycind IV 15 mg/kg q12 h Daptomycin 6 mg/kg IV q24 h
or
Linezolid 600 mg PO/IV q12 h
See recommended use of rifampin as a
companion drug for rifampin-susceptible
PJI treated with debridement and
retention or 1-stage exchange in text
Enterococcus spp,
penicillin-susceptible
Penicillin G 20–24 million units IV q24 h
continuously or in 6 divided doses
or
Ampicillin sodium 12 g IV q24 h
continuously or in 6 divided doses
Vancomycin 15 mg/kg IV q12 h
or
Daptomycin 6 mg/kg IV q24 h
4–6 wk. Aminoglycoside optional
Vancomycin should be used only in case
of penicillin allergy
or
Linezolid 600 mg PO or
IV q12 h
Enterococcus spp,
penicillin-resistant
Vancomycin 15 mg/kg IV q12 h Linezolid 600 mg PO or
IV q12 h
or
Daptomycin 6 mg IV q24 h
4–6 wk. Addition of aminoglycoside optional
Pseudomonas aeruginosa Cefepime 2 g IV q12 h Ciprofloxacin 750 mg PO bid 4–6 wk
or or 400 mg IV q12 h Addition of aminoglycoside optional
Meropeneme 1 g IV q8 h or Use of 2 active drugs could be considered
based on clinical circumstance of patient.
If aminoglycoside in spacer, and organism
aminoglycoside susceptible than double
coverage being provided with
recommended IV or oral monotherapy
Ceftazidime 2 g IV q8 h
Enterobacter spp Cefepime 2 g IV q12 h
or
Ertapenem 1 g IV q24 h
Ciprofloxacin 750 mg PO
or 400 mg IV q12 h
4–6 wk.
Enterobacteriaceae IV β-lactam based on in vitro susceptibilities
or
Ciprofloxacin 750 mg PO bid
4–6 wk
β-hemolytic streptococci Penicillin G 20–24 million units IV q24 h
continuously or in 6 divided doses
or
Ceftriaxone 2 g IV q24 h
Vancomycin 15 mg/kg IV q12 h 4–6 wk
Vancomycin only in case of allergy
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38. Four to 6 weeks of pathogen-speciﬁc intravenous or
highly bioavailable oral antimicrobial therapy is recommended
if, despite surgery, there is residual infected bone and soft
tissue (ie, hip disarticulation for THA infection, long-stem
TKA prosthesis where the prosthesis extended above the level
of amputation; Table 2; C-III).
39. Monitoring of outpatient intravenous antimicrobial
therapy should follow published guidelines (A-II) [6].
INTRODUCTION
Joint replacement is a highly effective intervention that signiﬁ-
cantly improves patients’ quality of life, providing symptom
relief, restoration of limb or joint function, improved mobility,
and independence. Prosthetic joint infection (PJI) remains one
of the most serious complications of prosthetic joint implanta-
tion. The cumulative incidence of PJI among the approximate-
ly 1 000 000 primary total hip arthroplasties (THAs) and total
knee arthroplasties (TKAs) performed in the United States in
2009 is approximately 1%–2% over the lifetime of the pros-
thetic joint, depending on the type of prosthesis and whether
the surgery is a primary or revision procedure [2, 7–10]. The
number of PJI is likely to increase: It is projected that by the
year 2030, approximately 4 million THAs and TKAs will be
performed per year in the United States [11].
The diagnosis of PJI can be difﬁcult and utilizes many differ-
ent diagnostic modalities including serologic, radiographic, and
microbiologic diagnostic tests. The management of PJI often
necessitates the need for surgical interventions and prolonged
courses of intravenous and oral antimicrobial therapy [1–4].
Despite a signiﬁcant amount of basic and clinical research in
this ﬁeld, many questions pertaining to the optimal diagnostic
strategies and management of these infections remain unan-
swered. The primary focus of these guidelines will be to
provide a consensus statement that addresses selected current
controversies in the diagnosis and treatment of infections
involving prosthetic joints. In many situations, the panel has
made recommendations based on expert opinion, realizing that
the amount of data to support a speciﬁc recommendation is
limited, and that there are diverse practice patterns which seem
to be equally effective for a given clinical problem.
An essential component of this therapeutic approach is the
strong collaboration between all involved medical and surgical
specialists (eg, orthopedic surgeons, plastic surgeons, infec-
tious disease specialists, general internists). It is anticipated
that consideration of these guidelines may help reduce mor-
bidity, mortality, and the costs associated with PJI. The panel
realizes that not all medical institutions will have the necessary
resources to implement all the recommendations in these
guidelines. Proper referral may need to occur.Ta
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The panel addressed the following clinical questions:
(I) What preoperative evaluation and intraoperative testing
should be performed to diagnose PJI and what is the deﬁni-
tion of PJI?
(II) What different surgical strategies should be considered
for treatment of a patient with PJI?
(III) What is the medical treatment for a patient with PJI
following debridement and retention of the prosthesis?
(IV) What is the medical treatment for a patient with PJI
following resection arthroplasty with or without planned
staged reimplantation?
(V) What is the medical treatment for a patient with PJI
following 1-stage exchange?
(VI) What is the medical treatment for a patient with PJI
following amputation?
PRACTICE GUIDELINES
“Practice guidelines are systematically developed statements to
assist practitioners and patients in making decisions about
appropriate health care for speciﬁc clinical circumstances” [12].
Attributes of good guidelines include validity, reliability, repro-
ducibility, clinical applicability, clinical ﬂexibility, clarity, multi-
disciplinary process, review of evidence, and documentation [12].
METHODOLOGY
Panel Composition
A panel of infectious disease specialists and an orthopedist,
drawn from North America and Europe, who are experts in
PJI was convened. The panelists had both clinical and labora-
tory experience with PJI.
Literature Review and Analysis
Two members of the panel (D. R. O., E. F. B.) initially re-
viewed the existing literature. The literature search, which in-
cluded the MEDLINE database between 1966 and 2011,
Cochrane library database, MD Consult, Up to Date, and the
National Guidelines Clearinghouse, was performed on multi-
ple occasions, the last being in April 2011 using multiple
search terms such as “joint prosthesis” and “PJI.” Hand search-
ing of bibliographies of identiﬁed articles was also undertaken.
Process Overview
In evaluating the evidence regarding the management of PJI,
the panel followed a process used in the development of other
Infectious Diseases Society of America (IDSA) guidelines. The
process included a systematic weighting of the quality of the
evidence and the grade of recommendation (Table 1) [5]. Rec-
ommendations for the medical management of PJI were
Table 3. Common Antimicrobials Used for Chronic Oral Antimicrobial Suppression (B-III Unless Otherwise Stated in Text)a,b
Microorganism Preferred Treatment Alternative Treatment
Staphylococci, oxacillin-susceptible Cephalexin 500 mg PO tid or qid
or
Cefadroxil 500 mg PO bid
Dicloxacillin 500 mg PO tid or qid
Clindamycin 300 mg PO qid
Amoxicillin-clavulanate 500 mg PO tid
Staphylococci, oxacillin-resistant Cotrimoxazole 1 DS tab PO bid
Minocycline or doxycycline100 mg PO bid
β-hemolytic streptococci Penicillin V 500 mg PO bid to qid
or
Amoxicillin 500 mg PO tid
Cephalexin 500 mg PO tid or qid
Enterococcus spp, penicillin susceptible Penicillin V 500 mg PO bid to qid
or
Amoxicillin 500 mg PO tid
Pseudomonas aeruginosa Ciprofloxacin 250–500 mg PO bid
Enterobacteriaceae Cotrimoxazole 1 DS tab PO bid β-lactam oral therapy based on in vitro
susceptibilities
Propionibacterium spp Penicillin V 500 mg PO bid to qid
or
Amoxicillin 500 mg PO tid
Cephalexin 500 mg PO tid or qid
Minocycline or doxycycline 100 mg PO
bid
Abbreviations: bid, twice daily; DS, double strength; PO, per oral; qid, 4 times daily; tid, 3 times daily.
a Antimicrobial dosage needs to be adjusted based on patients’ renal and hepatic function. Antimicrobials should be chosen based on in vitro susceptibility as
well as patient drug allergies, intolerances, and potential drug interactions or contraindications to a specific antimicrobial.
b Clinical and laboratory monitoring for efficacy and safety should occur based on the clinical judgment of the clinician caring for the patient. The possibility of
prolonged QTc interval and tendinopathy should be discussed and monitored when using fluoroquinolones. The possibility of Clostridium difficile colitis should
also be discussed when using any antimicrobial.
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derived primarily from case reports, nonrandomized retrospec-
tive case series, and 1 single-center randomized clinical trial.
Consensus Development Based on Evidence
Two members of the panel (D. R. O., E. F. B.) initially reviewed
existing literature and formulated a ﬁrst draft of the guidelines.
This ﬁrst draft was circulated electronically to all members of
the panel for comments and review. D. R. O. and E. F. B. then
incorporated these comments into a second and third draft
that was reviewed electronically. Topics on which consensus
could not be reached were discussed by the panel members
electronically, by teleconferences, and in person. All members
of the panel approved the ﬁnal draft. Feedback from external
peer reviews was obtained and changes made after review with
the entire panel. The guideline was reviewed and approved by
the IDSA Standards and Practice Guidelines Committee
(SPGC) and the Board of Directors prior to dissemination.
Guidelines and Conﬂicts of Interest
All members of the expert panel complied with the IDSA
policy on conﬂicts of interest, which requires disclosure of any
ﬁnancial or other interest that might be construed as consti-
tuting an actual, potential, or apparent conﬂict. Members of
the expert panel were provided IDSA’s conﬂicts of interest dis-
closure statement and were asked to identify ties to companies
developing products that might be affected by promulgation of
the guideline. Information was requested regarding employ-
ment, consultancies, stock ownership, honoraria, research
funding, expert testimony, and membership on company advi-
sory committees. The panel made decisions on a case-by-case
basis as to whether an individual’s role should be limited as a
result of a conﬂict. Potential conﬂicts are listed in the “Notes”
section at the end of the guideline.
Revision Dates
At annual intervals, the panel chair, the SPGC liaison advisor,
and the chair of the SPGC will determine the need for revi-
sions to the guideline on the basis of an examination of the
current literature. If necessary, the entire panel will be recon-
vened to discuss potential changes. When appropriate, the
panel will recommend revision of the guideline to the SPGC
and the IDSA Board for review and approval.
RECOMMENDATIONS FOR THE DIAGNOSIS
AND TREATMENT OF PJIs
I. What preoperative evaluation and intraoperative testing should
be performed to diagnose PJI and what is the deﬁnition of PJI?
Recommendations
Preoperative Evaluation (Figure 1)
1. Suspect PJI in patients with any of the following (B-III):
A sinus tract or persistent wound drainage over a joint
prosthesis, acute onset of a painful prosthesis, or any chronic
painful prosthesis at any time after prosthesis implantation,
particularly in the absence of a pain-free interval in the ﬁrst
few years following implantation or if there is a history of
prior wound healing problems or superﬁcial or deep infection.
2. Evaluation of the patient with a possible PJI should include
a thorough history and physical examination (C-III). Items that
should be obtained in the history include the type of prosthesis,
date of implantation, past surgeries on the joint, history of
wound healing problems following prosthesis implantation,
remote infections, current clinical symptoms, drug allergies and
intolerances, comorbid conditions, prior and current microbiolo-
gy results from aspirations and surgeries, and antimicrobial
therapy for the PJI including local antimicrobial therapy (C-III).
3. A test for sedimentation rate or C-reactive protein (CRP)
should be performed in all patients with a suspected PJI when
the diagnosis is not clinically evident. The combination of an
abnormal sedimentation rate and CRP seems to provide the
best combination of sensitivity and speciﬁcity (A-III).
4. A plain radiograph should be performed in all patients
with suspected PJI (A-III).
5. A diagnostic arthrocentesis should be performed in all pa-
tients with suspected acute PJI unless the diagnosis is evident
clinically and surgery is planned and antimicrobials can be
safely withheld prior to surgery. Arthrocentesis is also advised
in patients with a chronic painful prosthesis in whom there is
an unexplained elevated sedimentation rate or CRP (A-III) or
in whom there is a clinical suspicion of PJI. It may not be nec-
essary if in this situation surgery is planned and the result is not
expected to alter management. Synovial ﬂuid analysis should
include a total cell count and differential leukocyte count, as
well as culture for aerobic and anaerobic organisms (A-III). A
crystal analysis can also be performed if clinically indicated.
6. In PJI where the patient is medically stable, withholding
antimicrobial therapy for at least 2 weeks prior to collecting
synovial ﬂuid for culture increases the likelihood of recovering
an organism (B-III).
7. Blood cultures for aerobic and anaerobic organisms
should be obtained if fever is present, there is an acute onset
of symptoms, or if the patient has a condition or suspected
condition or concomitant infection or pathogen (eg, Staphylo-
coccus aureus) that would make the presence of a bloodstream
infection more likely (B-III).
8. Imaging studies such as bone scans, leukocyte scans,
magnetic resonance imaging (MRI), computed tomography
(CT), and positron emission tomography (PET) scans should
not be routinely used to diagnose PJI (B-III).
Intraoperative Diagnosis of PJI
9. Intraoperative histopathological examination of peripros-
thetic tissue samples is a highly reliable diagnostic test provided
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that a pathologist skilled in interpretation of periprosthetic
tissue is available. It should be performed at the time of revision
prosthetic joint surgery, when available, if the presence of infec-
tion is in doubt based on the clinical suspicion of the surgeon
and the results will affect management, for example, in deciding
between revision arthroplasty and 2-stage exchange (B-III).
10. At least 3 and optimally 5 or 6 periprosthetic intraoper-
ative tissue samples or the explanted prosthesis itself should
be submitted for aerobic and anaerobic culture at the time of
surgical debridement or prosthesis removal to maximize the
chance of obtaining a microbiologic diagnosis (B-II).
11. When possible (see above), withholding antimicrobial
therapy for at least 2 weeks prior to collecting intraoperative
culture specimens increases the yield of recovering an organ-
ism (A-II).
Deﬁnition of PJI
12. The presence of a sinus tract that communicates with
the prosthesis is deﬁnitive evidence of PJI (B-III).
13. The presence of acute inﬂammation as seen on histo-
pathologic examination of the periprosthetic tissue at the time
of surgical debridement or prosthesis removal as deﬁned by the
attending pathologist is highly suggestive evidence of PJI (B-II).
14. The presence of purulence without another known eti-
ology surrounding the prosthesis is deﬁnitive evidence of PJI
(B-III).
15. Two or more intraoperative cultures or combination of
preoperative aspiration and intraoperative cultures that yield
the same organism (indistinguishable based on common labo-
ratory tests including genus and species identiﬁcation or
common antibiogram) may be considered deﬁnitive evidence
of PJI. Growth of a virulent microorganism (eg, S. aureus) in a
single specimen of a tissue biopsy or synovial ﬂuid may
also represent PJI. One of multiple tissue cultures or a single
aspiration culture that yields an organism that is a common
contaminant (eg, coagulase-negative staphylococci, Propioni-
bacterium acnes) should not necessarily be considered evi-
dence of deﬁnite PJI and should be evaluated in the context of
other available evidence (B-III).
16. The presence of PJI is possible even if the above criteria
are not met; the clinician should use his/her clinical judgment
to determine if this is the case after reviewing all the available
preoperative and intraoperative information (B-III).
Evidence Summary
Diagnosis: Preoperative Evaluation
Classiﬁcation schemes for PJI are based on the timing of
infection after prosthesis implantation and a presumptive
mechanism of infection [13, 14]. These schemes may help the
clinician decide on treatment options. Infections that occur
within 1–3 months after implantation are classiﬁed as “early”
whereas infections that occur several months to 1–2 years fol-
lowing prosthesis implantation are classiﬁed as delayed. Both
types of infection are believed to be acquired most often
during prosthesis implantation. Early infections often will
present with local signs of cellulitis, erythema, swelling, pain,
drainage, and delayed wound healing and may or may not
have systemic symptoms such as fever and chills [4, 15].
Delayed infection, as well as chronic infection occurring many
years after prosthesis insertion, typically presents with vague
symptoms such as chronic pain without systemic symptoms as
well as a loose prosthesis. These scenarios can be difﬁcult to
distinguish from aseptic loosening by history and physical
exam. Although any painful prosthesis can represent a PJI, the
absence of an obvious mechanical reason for a painful pros-
thesis in the ﬁrst few years following implantation, a history of
prior wound healing problems, or superﬁcial or deep infection
should also raise the suspicion of PJI.
Late infections that occur more than 1–2 years after pros-
thesis implantation are either due to hematogenous seeding of
the prosthesis or a late manifestation of an infection acquired
during prosthesis insertion. Hematogenous infections may
also occur early after prosthesis insertion [16]. Late infections
are often characterized by an acute septic arthritis syndrome
with sudden onset of pain in the setting of concomitant or
recent infection occurring elsewhere in the body (eg, skin
and soft tissue, respiratory tract, or urinary tract infections)
[13, 14, 16–18].
At the time of diagnosis of PJI, information related to the
type of prosthesis, date of implantation, past surgeries on the
joint, clinical symptoms, drug allergies and intolerances, co-
morbid conditions, and prior and current antimicrobial
therapy for the PJI including local antimicrobial therapy
should be obtained by the clinician [19, 20].
A variety of laboratory and radiographic tests are available
to aid the clinician in the diagnosis of PJI in situations where
the diagnosis is unclear [21–23]. Plain radiographs are ob-
tained in most if not all situations but lack sensitivity and spe-
ciﬁcity [24]. They rarely show clear evidence of infection such
as transcortical sinus tract but can show other reasons for
chronic pain and serve as a baseline for following any diag-
nostic or therapeutic procedures. Serial exams may be the
most helpful. Radionuclide scans, CT, MRI, and FDG PET
scanning are rarely utilized due to either their expense, lack of
availability, or image distortion due to the prosthesis com-
pared with other tests [1, 4, 22]. If any of these tests are
utilized, a leukocyte scan in combination with a technetium-
labeled bone scan is the most often used because of availability
and reasonable sensitivity and speciﬁcity. The utility of the
white blood cell count, CRP, and erythrocyte sedimentation
rate have been discussed at length by multiple authors [1, 4,
21, 25, 26]. These tests are obviously not necessary to make a
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diagnosis when infection is evident, for example, when a sinus
tract is present or there is an acute septic arthritis. They are
nonspeciﬁc tests and are associated with a signiﬁcant false-
positive rate particularly immediately after prosthesis implan-
tation or in patients with inﬂammatory arthritis [21]. Cutoffs
that predict PJI in this setting have recently been proposed but
require validation [27]. Baseline values if available may be
helpful. CRP seems to be more accurate than the sedimenta-
tion rate when evaluating a patient with a painful prosthesis
and suspected chronic PJI [21, 26, 28, 29]. Combining both the
sedimentation rate and the CRP so that either both are posi-
tive or both are negative may provide the best combination of
positive and negative predictive values [21, 28–30]. There are
much less data on the use of interleukin 6 (IL-6) and procalci-
tonin, although IL-6 looks very promising [26, 31, 32]. Blood
cultures to exclude concomitant bacteremia should be ob-
tained if the patient is febrile, has a clinical condition or con-
comitant infection, or has a pathogen known to cause
metastatic infection (eg, S. aureus) that would make bactere-
mia more likely. Suspicion of infective endocarditis or the
presence of a cardiac pacemaker, for example, should also
warrant the consideration of obtaining blood cultures and,
depending on the level of suspicion of the presence of infective
endocarditis, a transesophageal echocardiogram.
Synovial ﬂuid obtained by preoperative aspiration can be
submitted for cell count and differential, Gram stain, and
aerobic and anaerobic culture. A diagnostic arthrocentesis
should be performed in all patients with a suspected acute PJI
unless the diagnosis is evident clinically and surgery is planned
and antimicrobials can be withheld prior to surgery. Arthro-
centesis is also advised in patients with a chronic painful pros-
thesis in whom there is an elevated sedimentation rate or CRP
level or in whom there is a high clinical suspicion of PJI. It may
not be necessary in this situation if surgery is planned and the
result is not expected to alter management [19, 21, 22, 30, 33].
A synovial ﬂuid leukocyte differential of >65% neutrophils or a
leukocyte count of >1700 cells/μL had 97% and 94% sensitivity,
respectively, to detect infection in a total knee replacement in
patients without underlying inﬂammatory joint disease and
who were more than 6 months from TKA implantation [34].
This cutoff is much lower than that used to suggest infection in
native joint septic arthritis. In all patients with a THA-associat-
ed infection in a recent study, a leukocyte count of 4200 cells/
μL had a sensitivity of 84% and a speciﬁcity of 93% to detect
PJI [35]. Its utility in other types of prostheses is the subject of
ongoing research. A synovial ﬂuid leukocyte count >27 800
cells/μL and differential of 89% polymorphonuclear neutro-
phils has recently been shown to be predictive of TKA infection
in the early postoperative period [27]. Thus the cell count and
its ability to predict infection must be interpreted in light of the
type of prosthesis and the time from prosthesis implantation.
Diagnosis: Intraoperative Evaluation
Intraoperative histopathological examination of the peri-
prosthetic tissue has a relatively high sensitivity (>80%) and
speciﬁcity (>90%) and is used to decide if revision arthroplasty
vs resection arthroplasty should be performed when a skilled
pathologist is available and the preoperative evaluation has
failed to conﬁrm PJI [21, 30, 36–38]. Unfortunately, the results
can be dependent on appropriate sampling of the tissue har-
boring the infection and the expertise of the pathologist since
not all centers will have pathologists who are experienced in
this type of histopathologic analysis. There are recent data sug-
gesting that acute inﬂammation is less common in infection
due to low-virulence organisms [39].
At least 3 and optimally 5 or 6 periprosthetic intraoperative
samples from the most suspicious areas of tissue as deemed by
the orthopedic surgeon should be obtained for aerobic and
anaerobic culture for the optimal diagnosis of PJI [40, 41].
Submitting fewer than 5–6 specimens leads to a decrease in
sensitivity of culture as a diagnostic test. There is no standard
time that microbiology laboratories incubate periprosthetic
tissue specimens. The optimal duration of incubation of peri-
prosthetic tissue specimens is unknown, but prolonged incu-
bation of up to 14 days may help with pathogen isolation,
particularly Propionibacterium species, a common pathogen in
total shoulder arthroplasty infection [42]. Novel processing
techniques may also help with pathogen identiﬁcation [43].
When possible, withholding antimicrobial therapy for at least
2 weeks prior to collecting the specimens increases the yield of
recovering an organism [41]. The decision to withhold antimi-
crobial prophylaxis at the time of revision total joint surgery
to optimize tissue culture ascertainment should be based on
the preoperative risk of PJI. If the risk is low based on the
results of the history, exam, sedimentation rate, CRP level, and
preoperative aspiration, then antimicrobial prophylaxis should
be given normally according to standard guidelines. If the risk
of PJI is high, then withholding antimicrobial prophylaxis
prior to revision total joint surgery seems appropriate to max-
imize the yield of tissue cultures. The explanted prosthesis
itself can also be submitted for Soniﬁcation and subsequent
aerobic and anaerobic culture. Sonication has been used to
dislodge bacteria from the surface of the prosthesis, and
culture of the prosthesis ultrasonicate can improve the sensi-
tivity of aerobic and anaerobic culture compared to traditional
tissue culture [41, 44]. The sensitivity of a periprosthetic soni-
cate-ﬂuid culture for the diagnosis of prosthetic hip and knee
infection was higher than that of culturing a single sample of
periprosthetic tissue, namely, 78.5% compared with 60.8%
(P < .001) in the original study utilizing this technique [41].
This technique is not validated for the isolation of fungal and
mycobacterial organisms. The Gram stain is not routinely
useful as a diagnostic test owing to low sensitivity on tissue
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specimens but has increased sensitivity on ultrasonicate ﬂuid
[40, 41, 45, 46]. As with other uses, false-positive Gram stains
due to laboratory contamination have been reported [47]. In
the situation of a positive Gram stain and negative tissue cul-
tures, the clinician will need to decide after review of the clini-
cal circumstances of the speciﬁc case, including the use of
prior antimicrobial therapy, and discussion with the microbi-
ology laboratory if the Gram stain result is helpful in tailoring
antimicrobial therapy. Rapid diagnostic tests such as polymer-
ase chain reaction are still not yet available for routine clinical
application [48–50].
Deﬁnition of PJI
There is no standard deﬁnition of what constitutes PJI;
therefore, interpretation of the literature related to the treat-
ment of these infections is difﬁcult [51]. The diagnosis of PJI
is obvious if multiple cultures from specimens surrounding
the prosthesis yield identical microorganisms, if the prosthe-
sis ultrasonicate ﬂuid is positive, if purulence is observed sur-
rounding the prosthesis without another known etiology
such as a failed metal-on-metal arthroplasty [52], or if a
sinus tract that communicates with the prosthetic device is
present. The diagnosis of PJI can be more difﬁcult if typical
signs or symptoms of infection are lacking. For instance, the
presence of periprosthetic loosening of a joint arthroplasty or
joint pain can be the result of occult infection or other non-
infectious etiologies. The presence of acute inﬂammation
consistent with infection on histopathological examination
(as determined by a pathologist) is highly suggestive evidence
of the presence of PJI (though it should be noted that there
are multiple deﬁnitions of what constitutes acute inﬂamma-
tion of periprosthetic tissues at the time of revision arthro-
plasty and signiﬁcant variability among pathologists in the
interpretation of these specimens) [21, 36–38, 53]. The panel
is of the opinion that 2 or more positive cultures from intra-
operative specimens represent deﬁnitive evidence of infection.
Although a study by Atkins et al found an optimal posttest
probability of infection with 3 or more positive cultures, they
also demonstrated that at the time of revision hip or knee
surgery, compared with histopathologic evidence of infection,
2 positive intraoperative cultures provided acceptable sensitiv-
ity and speciﬁcity without requiring an impractical amount of
tissue specimens to be processed by the laboratory [40]. A
single positive periprosthetic tissue culture that yields an or-
ganism that is a common contaminant (eg, coagulase-negative
staphylococci, Propionibacterium acnes) should not necessarily
be considered evidence of deﬁnite PJI and should be evaluated
in the context of other available evidence [40, 51]. The clini-
cian should use clinical judgment when the presence of PJI is
not obvious and decide if infection is present after reviewing
the history, exam, and preoperative and intraoperative tests.
II. What different surgical strategies should be considered for
treatment of a patient with PJI?
Recommendations
17. The ultimate decision regarding surgical management
should be made by the orthopedic surgeon with appropriate
consultation (eg, infectious diseases, plastic surgery) as necessary
(C-III).
18. Patients diagnosed with a PJI who have a well-ﬁxed pros-
thesis without a sinus tract who are within approximately 30
days of prosthesis implantation or fewer than 3 weeks of onset
of infectious symptoms should be considered for a debride-
ment and retention of prosthesis strategy (Figure 2; A-II). Pa-
tients who do not meet these criteria but for whom alternative
surgical strategies are unacceptable or high risk may also be
considered for a debridement and retention strategy, but
relapse of infection is more likely (B-III).
19. A 2-stage exchange strategy is commonly used in the
United States and is indicated in patients who are not candi-
dates for a 1-stage exchange who are medically able to
undergo multiple surgeries and in whom the surgeon believes
reimplantation arthroplasty is possible, based on the existing
soft tissue and bone defects (Figure 3; B-III). Obtaining a pre-
revision sedimentation rate and CRP is recommended by the
panel to assess the success of treatment prior to reimplanta-
tion (C-III). The panel believes that in selected circumstances,
more than one 2-stage exchanges can be successful if the ﬁrst
one fails (C-III).
20. A 1-stage or direct exchange strategy for the treatment of
PJI is not commonly performed in the United States but may be
considered in patients with a THA infection who have a good
soft tissue envelope provided that the identity of the pathogens is
known preoperatively and susceptible to oral antimicrobials with
excellent oral bioavailability. There may be a greater risk of
failure if bone grafting is required and effective antibiotic impreg-
nated bone cement cannot be utilized (Figure 3; C-III).
21. Permanent resection arthroplasty may be considered in
nonambulatory patients; patients with limited bone stock,
poor soft tissue coverage, or infections due to highly resistant
organisms for which there is limited medical therapy; patients
with a medical condition precluding multiple major surgeries;
or patients who have failed a previous 2-stage exchange in
which the risk of recurrent infection after another staged
exchange is deemed unacceptable (Figure 4; B-III).
22. Amputation should be the last option considered but may
be appropriate in selected cases. Except in emergent cases, referral
to a center with specialist experience in the management of PJI is
advised before amputation is carried out (Figure 4; B-III).
Evidence Summary
The most commonly used surgical treatments for PJI include
debridement and retention of the prosthesis, 1- or 2-stage
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(staged) exchange, resection arthroplasty, arthrodesis, and am-
putation [54]. There are no published randomized clinical
trials to address optimal selection of these surgical procedures.
The available data consist of single-center noncomparative
cohort studies and a decision analysis based on these cohort
studies [55]. Infectious disease clinicians should work closely
with the orthopedist to determine the ultimate surgical strat-
egy selected for an individual patient.
Many factors inﬂuence the ultimate surgical management
chosen for a given patient. Examples of these factors could
include duration of symptoms, joint age (early, delayed, or
late), infecting pathogen and its susceptibility pattern, prosthe-
sis stability, and the patient’s preexisting medical comorbidi-
ties. Other factors, such as the quality of the periprosthetic
soft tissue, the options available for successful reconstructive
surgery after resection arthroplasty, the expertise of the clini-
cian(s), and the patient’s preferences, also inﬂuence the surgi-
cal management.
The panel reviewed available published data on the surgical
management of THA and TKA. Figures 1–3 show treatment
algorithms for initial surgical management following these
procedures that are based on published data and the panel’s
expert opinion. The ﬁnal operative decision is up to the treat-
ing orthopedic surgeon after consultation with the patient.
Debridement without removal of the infected prosthesis
can be done via either an open arthrotomy or arthroscopy
[55–80]. Open arthrotomy allows for an extensive debride-
ment and polyethylene liner exchange and is the most exten-
sively described technique. There are increasing data that
arthroscopy provides worse outcomes compared with open
arthrotomy [62, 76]. Debridement of the infected prosthesis
without removal of the prosthetic joint is associated with a
success rate of 14%–100% [56–58, 60–62, 64, 66–74, 76–78,
81–84]. This surgical modality is typically reserved for patients
with a well-ﬁxed prosthesis with early postoperative PJI (<30
days) or patients with short duration of symptoms in hema-
togenous infection. There is an increased risk of treatment
failure reported in patients with a sinus tract [2, 67] and infec-
tions due to certain organisms such as S. aureus when not
treated with a rifampin combination [67], methicillin-resistant
S. (MRSA), and gram-negative organisms [85–90]. Treatment
failure following debridement and retention includes meeting
the deﬁnition of infection mentioned previously as well as per-
sistent pain that is intolerable to the patient. Following an
algorithmic approach seems to provide beneﬁt in outcome
and is encouraged by the panel, although different algorithms
exist and individual judgment must be used in all situations
[2, 80, 83, 85, 88, 91]. There have been recent reports suggest-
ing there may be a worse outcome for 2-stage exchange
procedures following a failed debridement and retention pro-
cedure. Further data on this are warranted to help clinicians
decide on the overall utility of the debridement and retention
strategy [84, 92].
A 1-stage exchange or revision procedure involves excision
of all prosthetic components and poly methyl methacrylate
cement, debridement of devitalized bone and soft tissues, pros-
thesis removal, and implantation of a new prosthesis. This pro-
cedure is associated with a success rate of 80%–90% in patients
with THA infection and its success is likely attributable to the
extent of the debridement [93–95]. Most series use antibiotic im-
pregnated cement to ﬁx the new prosthesis [94, 96]. A recent deci-
sion analysis favored direct exchange over 2-stage exchange [95].
There are much fewer data for the use of this procedure for
prosthetic joints other than a THA or without antibiotic im-
pregnated cement and with bone graft [94, 97–99]. There is
more literature on the utilization of this procedure from Euro-
pean than US institutions for THA infection. This difference
may be owing to a low number of patients in the United States
that are eligible for this type of procedure [100]. Published cri-
teria for these procedures have included a relatively healthy
patient with adequate bone stock and soft tissues, and patients
with an easily treatable organism, which usually has been
deﬁned as streptococci other than enterococci, methicillin-sen-
sitive staphylococci, and nonpseudomonal gram-negative or-
ganisms. Enterococci and fungal organisms, as well as
infection due to small-colony variants, have been thought to be
difﬁcult to treat [2, 88, 94, 101]. The panel believes that the
pathogen at a minimum should be susceptible to oral agents
with excellent bioavailability. One-stage exchange is typically
not recommended in patients with a sinus tract. Potential ad-
vantages of this single exchange procedure result from saving
the patient and the healthcare system an additional surgery,
and include lower morbidity rate and lower cost [91, 95].
Staged exchange or 2-stage exchange is most often used in
the United States for the treatment of chronic PJI associated
with prosthesis loosening [102–116]. This procedure is report-
ed to have an overall incidence of success of 87% in a recent
review [4]. This strategy involves removal of all infected pros-
thetic components and cement followed by debridement of in-
fected periprosthetic tissue. Local antimicrobial-impregnated
cement and devices are commonly used in the treatment of
PJI. The antibiotic-impregnated cement is either premixed or
mixed with an antimicrobial by the surgeon in the operating
room. The clinician should be aware of the potential for sys-
temic toxicity of local antimicrobial delivery devices, although
this rarely occurs [112, 115]. Antimicrobial impregnated static
or articulating spacers are often used to manage dead space
and deliver local antimicrobial therapy until a permanent
prosthesis is placed [108, 117]. Some panel members do not
recommend spacers for MRSA infection, infection due to
small-colony variants, or fungi as they believe that the use of
spacers in these settings may be detrimental to the eradication
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of infection (W. Z.) [2, 118]. Reports of successful use of
spacers for MRSA PJI have been published [119]. The time
from resection arthroplasty to reimplantation varies signiﬁ-
cantly from 2 weeks to several months. The use of antibiotic-
impregnated cement and spacers has not been evaluated in
randomized controlled trials [105, 108]. Systemic antimicrobi-
als are administered following resection for 4–6 weeks in
many centers (Table 2). Selected centers use the serum bacter-
icidal test to guide proper dosing of antimicrobial therapy.
None of the panel members have any experience using the
serum bactericidal titer for this indication [120].
A delayed or second stage then occurs when a new prosthe-
sis is reimplanted, weeks to months after resection arthro-
plasty, depending on the type of prosthesis. Both cemented
and noncemented prostheses are utilized depending on the
technical factors. The US Food and Drug Administration has
approved several aminoglycoside-containing cements for ﬁxa-
tion of the prosthesis at the time of reimplantation [107].
Ideal patients for this strategy are patients with chronic in-
fections with adequate bone stock, who are medically ﬁt and
willing to undergo at least 2 surgeries [2, 4, 121–123]. Patients
with sinus tracts or with difﬁcult-to-treat organisms such as
MRSA, enterococci, and Candida species would also potential-
ly qualify for this procedure. In earlier cohort studies, early
reimplantation within 3 weeks after resection resulted in a
higher failure rate [110]. Cohort studies from Europe revealed
a favorable outcome with reimplantation within 2–6 weeks
while systemic antimicrobials are still being administered in
selected situations when the infection is not due to MRSA,
enterococci, multidrug-resistant gram-negative organisms [2].
Delayed reimplantation after 4–6 weeks of intravenous antimi-
crobial therapy and an antibiotic-free period of 2–8 weeks has
been highly successful. This strategy is used frequently in the
United States [13, 104, 106, 120]. The use of an articulating
spacer may allow for a more extended antibiotic-free period
without an effect on the functional outcome. More recent
cases series describe a successful outcome with very short or
no intravenous antimicrobial therapy when antimicrobial
impregnated spacers are used, although the panel does not
currently recommend this approach [109, 113]. Earlier reim-
plantation or the use of an articulating spacer may improve
function, especially in the knee joint.
The period of time between resection arthroplasty and re-
implantation can be used to evaluate for residual infection by
clinical assessment and laboratory tests as well as intraopera-
tive inspection and pathologic review of the periprosthetic
tissue at the time of reimplantation. The panel does recom-
mend obtaining a prerevision sedimentation rate and CRP to
assess the success of treatment prior to reimplantation. Al-
though recent studies suggest that a persistently elevated CRP
level and sedimentation rate may not be accurate in predicting
persistent PJI after resection arthroplasty, the need for subse-
quent debridement must be interpreted in the context of the
entire clinical picture when deciding timing of reimplantation
[124–126]. Synovial ﬂuid examination and joint aspirate cul-
tures prior to reimplantation have been advocated by some in-
vestigators [125–127].The panel did not endorse this testing in
all patients but thought it could be used in selected cases when
the clinician was concerned about persistent infection. In cases
of suspected infection based on preoperative and intraoperative
ﬁndings by the surgeon or a pathologist’s review of peripros-
thetic tissue for acute inﬂammation at the time of delayed
reimplantation, another debridement is typically performed [53].
If infection reoccurs again after a 2-stage exchange has been
accomplished, the success rate with a second 2-stage exchange
attempt may be lower than with the ﬁrst attempt [102, 116,
128–130]. The panel believes, however, that in selected cir-
cumstances a second 2-stage exchange can be successful.
Permanent resection arthroplasty involves the resection of
the infected prosthesis without reimplantation [94, 131–136].
After TKA resection, the knee may be arthrodesed to allow
weight bearing. Arthrodesis can be accomplished with either
an external ﬁxator or intramedullary nail [137, 138]. Currently
these procedures have limited indications. They have been uti-
lized in nonambulatory patients; patients with limited bone
stock, poor soft tissue coverage, or infections due to highly
resistant organisms for which there is no or limited medical
therapy; patients with a medical condition precluding major
surgery; or patients who have failed 2-stage exchange in which
the risk of recurrent infection after a staged exchange is
deemed unacceptable. This procedure often is done in an
effort to avoid amputation in ambulatory patients. It is usually
followed by administration of 4–6 weeks of intravenous anti-
microbials or highly bioavailable oral antimicrobials. Eradica-
tion of infection occurs in 60%–100% of cases, which is less
than the reported efﬁcacy of staged exchange. This difference
of outcome may be due to selection bias.
Amputation may be required in selected cases such as the
presence of necrotizing fasciitis not responding to debridement
alone, severe bone loss, the inability or failure to achieve soft
tissue coverage, or if a prior attempt at resection arthroplasty
to control infection has failed [4, 139–142]. This procedure
can also be considered if the patient’s long-term functional
outcome would be better with amputation rather than resection
arthroplasty or arthrodesis (eg, some nonambulatory patients).
III. What is the medical treatment for a patient with PJI
following debridement and retention of the prosthesis?
Recommendations
Staphylococcal PJI
23. Two to 6 weeks of a pathogen-speciﬁc intravenous
antimicrobial therapy (Table 2) in combination with
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rifampin 300–450 mg orally twice daily followed by rifam-
pin plus a companion oral drug for a total of 3 months for
a THA infection and 6 months for a TKA infection (A-I).
Total elbow, total shoulder, and total ankle infections may
be managed with the same protocols as THA infections (C-
III). Recommended oral companion drugs for rifampin
include ciproﬂoxacin (A-I) or levoﬂoxacin (A-II). Second-
ary companion drugs to be used if in vitro susceptibility,
allergies, intolerances, or potential intolerances support the
use of an agent other than a quinolone include but are not
limited to co-trimoxazole (A-II), minocycline or doxycy-
cline (C-III), or oral ﬁrst-generation cephalosporins (eg,
cephalexin) or antistaphylococcal penicillins (eg, dicloxacil-
lin; C-III). If rifampin cannot be used because of allergy,
toxicity, or intolerance, the panel recommends 4–6 weeks
of pathogen-speciﬁc intravenous antimicrobial therapy
(B-III).
24. Monitoring of outpatient intravenous antimicrobial
therapy should follow published guidelines (A-II) [6].
25. Indeﬁnite chronic oral antimicrobial suppression may
follow the above regimen with cephalexin, dicloxacillin, co-
trimoxazole, or minocycline based on in vitro susceptibility,
allergies, or intolerances (Table 3; B-III). Rifampin alone for
chronic suppression is not recommended and rifampin com-
bination therapy is also not generally recommended. One
member of the panel uses rifampin combination therapy for
chronic suppression in selected situations (A. R. B.).The rec-
ommendation regarding using suppressive therapy after ri-
fampin treatment was not unanimous (W. Z., D. L.). Clinical
and laboratory monitoring for efﬁcacy and toxicity is advis-
able (Table 3). The decision to offer chronic suppressive
therapy must take into account the individual circumstances
of the patient including the ability to use rifampin in the
initial phase of treatment, the potential for progressive
implant loosening and loss of bone stock, and the hazards of
prolonged antibiotic therapy; it is therefore generally reserved
for patients who are unsuitable for, or refuse, further
exchange revision, excision arthroplasty, or amputation.
PJI Due to Other Organisms
26. Four to 6 weeks of pathogen-speciﬁc intravenous or
highly bioavailable oral antimicrobial therapy (Table 2; B-II).
27. Monitoring of outpatient intravenous antimicrobial
therapy should follow published guidelines (A-II) [6].
28. Indeﬁnite chronic oral antimicrobial suppression may
follow the above regimens (Table 3) based on in vitro sensitiv-
ities, allergies, and intolerances (B-III). Chronic suppression
after ﬂuoroquinolone treatment of gram-negative bacilli was not
unanimously recommended (W. Z., D. L.). Clinical and labora-
tory monitoring for efﬁcacy and toxicity is advisable (Table 3).
Similar considerations regarding hazards and effectiveness
apply to those above.
Evidence Summary
Following debridement and retention of staphylococcal PJI,
the panel advocates the use of a combination of a β-lactam or
vancomycin with rifampin for 2–6 weeks, assuming the organ-
isms are susceptible in vitro to these antimicrobials and rifam-
pin can be utilized safely (Table 2) [74, 78]. Rifampin should
always be used in combination with other antimicrobials
because of its activity against bioﬁlm organisms and because
of a high rate of emergence of resistance if used as monother-
apy [2, 77, 143]. If the staphylococci are oxacillin susceptible,
nafcillin, oxacillin, or cefazolin are appropriate intravenous
companion drugs for rifampin. The use of ceftriaxone for
oxacillin-susceptible staphylococci is discussed elsewhere (re-
section arthroplasty). If the isolate is oxacillin resistant, vanco-
mycin is the primary companion drug of choice [78]. If the
organism is resistant to both oxacillin and vancomycin, or if
the patient is allergic or intolerant to these drugs, alternatives
include daptomycin or linezolid [88, 144–148]. Although van-
comycin has well-known potential toxicities including leuko-
penia, ototoxicity, and, rarely, nephrotoxicity, it must be
remembered that linezolid has been associated with cytope-
nias, peripheral neuropathy, and optic neuritis and serotonin
syndrome in patients treated concurrently with monoamine
oxidase inhibitors or serotonin reuptake inhibitors and lactic
acidosis [149–155]. Severe anemia may also be more common
in patients with preexisting anemia prior to the use of linezol-
id [156]. In addition, one article has suggested that the con-
comitant use of rifampin may decrease levels of linezolid
[150]. However, other authors have suggested that this combi-
nation is efﬁcacious in humans and experimental models
[147, 157]. There is even less published experience with dapto-
mycin [158–163]. Monitoring for daptomycin toxicity includ-
ing rhabdomyolysis, neuropathy, and eosinophilic pneumonia
is important [6, 164]. It is recommended that statins be
stopped, if possible, while administering daptomycin. Emer-
gence of daptomycin resistance on therapy to daptomycin has
occurred [163, 165]. Emergence of daptomycin resistance was
not observed in a recent experimental model [158]. In addi-
tion, with daptomycin doses corresponding to 6 mg/kg in
humans, no emergence of rifampin resistance was observed
when both drugs were used in combination. For patients with
nonstaphylococcal PJI treated with debridement and retention,
the panel agrees on using an induction course of intravenous
antimicrobial therapy or highly available oral therapy as
outlined in Table 2 based on in vitro sensitivity testing. The
use of quinolones after debridement and retention for
susceptible aerobic gram-negative PJI may improve the
outcome [166, 167].
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The role of quinolone/rifampin combination in the treatment
of staphylococcal orthopedic implant-related infection treated
with debridement and component retention was analyzed in a
single randomized clinical trial of susceptible staphylococcal in-
fections of prosthetic joints and fracture ﬁxation devices [78].
Although the intent-to-treat analysis did not show a statistically
signiﬁcant difference, there was a statistical beneﬁt in using
combination therapy with ciproﬂoxacin and rifampin in those
patients who were able to complete therapy. A recent cohort
also suggests excellent efﬁcacy of the ciproﬂoxacin and rifampin
combination [62]. Monitoring for adverse effects to quinolones
(including but not limited to tendinopathy, prolonged QTc)
and rifampin (hepatitis, signiﬁcant drug interactions) as with
all antimicrobials is vital. Cohort studies suggest that levoﬂoxa-
cin is also safe and effective in this setting and the improved in
vitro antistaphylococcal activity may favor its use in susceptible
isolates [168]. In patients with quinolone-resistant isolates,
possible oral companion drugs for rifampin, assuming the or-
ganism is susceptible in vitro, can include co-trimoxazole, min-
ocycline or doxycycline, or oral ﬁrst-generation cephalosporins
such as cephalexin. Fusidic acid as a companion drug has been
used in Europe [57]. The oral companion drug/rifampin com-
bination is utilized to complete a total of 3–6 months (3
months for THA PJI and 6 months for TKA PJI).
Chronic Oral Antimicrobial Suppression
The panel could not agree on the use and duration of
chronic suppression following the induction course of intrave-
nous antimicrobial therapy in nonstaphylococcal PJI or fol-
lowing the 3- to 6-month course of quinolone or other
companion drug/rifampin in staphylococcal PJI treated with
debridement and component retention. Some members of the
panel (D. L., W. Z.) would never use chronic suppression after
rifampin combination therapy; others would recommend the
use of chronic suppression in all cases of PJI treated with de-
bridement and component retention, assuming the patient tol-
erates the medication without difﬁculty, whereas others would
use it selectively in elderly or immunosuppressed patients, pa-
tients with a staphylococcal PJI in which rifampin is not uti-
lized, elderly patients with nonstaphylococcal PJI, or patients
whose comorbidities would not allow additional surgery or in
whom additional surgery may be limb-threatening in case of
treatment failure. Rifampin alone and linezolid should not be
used for indeﬁnite chronic suppression. Rifampin combina-
tion therapy is also not generally recommended; one member
of the panel uses rifampin combination therapy for chronic
suppression in selected situations (A. R. B.) [62]. Table 3 sum-
marizes the antimicrobials that are commonly used for
chronic suppression [81, 169–171].
If chronic oral suppression is not utilized or discontinued,
recent data would suggest that there is a 4-fold increased risk
of treatment failure at the time suppression is discontinued,
and that this risk of failure is greatest in the 4 months follow-
ing antimicrobial discontinuation [62]. However, in this study
the majority of patients who had their chronic suppression
discontinued did not suffer treatment failure, suggesting that
many patients are cured without the use of chronic suppression
but that deﬁning that group of patients can be difﬁcult [62].
Thus if this pathway is chosen, monitoring for treatment
failure early after treatment discontinuation is chosen is im-
portant. The investigators of this study also pointed out that
the vast majority of their study patients received at least 6
months of intravenous or oral antimicrobial therapy. Recom-
mending the use of chronic suppression in young patients is
particularly controversial and must be done on a case-by-case
basis. It is advisable that patients on chronic oral antimicrobial
suppression be monitored both for clinical failure and for
antimicrobial toxicity (Table 3).
IV. What is the medical treatment for a patient with PJI
following resection arthroplasty with or without planned staged
reimplantation?
Recommendations
29. Four to 6 weeks of pathogen-speciﬁc intravenous or
highly bioavailable oral antimicrobial therapy is recommended
(Table 2; A-II).
30. Monitoring of outpatient intravenous antimicrobial
therapy should follow published guidelines (A-II) [6].
Evidence Summary
In the United States, patients undergoing resection arthro-
plasty typically receive 4–6 weeks of intravenous or highly bio-
available oral antimicrobial therapy between resection
arthroplasty and reimplantation [13, 14, 104]. Most panel
members would use 6 weeks of therapy for more virulent or-
ganisms such as S. aureus. Speciﬁc recommended antimicrobi-
als are delineated in Table 2. Cefazolin or nafcillin is
recommended for oxacillin-sensitive staphylococci and vanco-
mycin for MRSA [2, 88, 104]. There was not a consensus on
the use of ceftriaxone as a single agent for oxacillin-susceptible
staphylococcal infections. The panel recognizes that there are
retrospective cohort data with short duration of follow-up
available to support its use in bone and joint infections and
PJI due to oxacillin-susceptible staphylococci [172–174]. Ri-
fampin is not routinely recommended as a companion drug in
this situation as all foreign material has been removed and
there are no clinical data supporting the need for a bioﬁlm
active agent in this setting, while the risk of rifampin toxicity
is not minimal. In patients undergoing 2-stage exchange, no
antimicrobial therapy should be used prior to planned resec-
tion arthroplasty until tissue cultures or ultrasonicate ﬂuid cul-
tures have been obtained, in order to improve the diagnostic
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yield of tissue cultures or ultrasonicate. However, prophylaxis
according to standard guidelines to prevent surgical site infec-
tion at the time of total joint arthroplasty should be used prior
to reimplantation arthroplasty if it is believed the prior PJI has
been eradicated.
V. What is the medical treatment for a patient with PJI
following 1-stage exchange?
Recommendations
Staphylococcal PJI
31. Two to 6 weeks of pathogen-speciﬁc intravenous anti-
microbial therapy in combination with rifampin 300–450 mg
orally twice daily followed by rifampin plus a companion oral
drug for a total of 3 months is recommended (Table 2; C-III).
Recommended oral companion drugs for rifampin include
ciproﬂoxacin (A-I) or levoﬂoxacin (A-II). Secondary compan-
ion drugs to be used if in vitro susceptibility, allergies, intoler-
ances, or potential intolerances support the use of an agent
other than a quinolone include but are not limited to co-tri-
moxazole (A-II), minocycline or doxycycline (B-III), or oral
ﬁrst-generation cephalosporins (eg, cephalexin) or antistaphy-
lococcal penicillins (eg, dicloxacillin; C-III). If rifampin
cannot be used because of allergy, toxicity, or intolerance then
the panel recommends 4–6 weeks of pathogen-speciﬁc intrave-
nous antimicrobial therapy.
32. Monitoring of outpatient intravenous antimicrobial
therapy should follow published guidelines (A-II) [6].
33. Indeﬁnite chronic oral antimicrobial suppression may
follow the above regimen with either cephalexin, dicloxacillin,
co-trimoxazole, or minocycline or doxycycline based on in
vitro susceptibility, allergies, or intolerances (Table 3; B-III).
Rifampin alone is not recommended for chronic suppression,
and rifampin combination therapy is also not generally rec-
ommended. One member of the panel uses rifampin combina-
tion therapy for chronic suppression in selected situations
(A. R. B.). The recommendation regarding using suppressive
therapy after rifampin treatment was not unanimous (D. L.,
W. Z.). Clinical and laboratory monitoring for efﬁcacy and
toxicity is advisable. The decision to offer chronic suppressive
therapy must take into account the individual circumstances
of the patient including the ability to use rifampin in the
initial phase of treatment, the potential for progressive
implant loosening and loss of bone stock, and the hazards of
prolonged antibiotic therapy; it is therefore generally reserved
for patients who are unsuitable for, or refuse, further exchange
revision, excision arthroplasty, or amputation.
PJI Due to Other Organisms
34. Four to 6 weeks of pathogen-speciﬁc intravenous or
highly bioavailable oral antimicrobial therapy is recommended
(Table 2; A-II).
35. Monitoring of outpatient intravenous antimicrobial
therapy should follow published guidelines (A-II) [6].
36. Indeﬁnite chronic oral antimicrobial suppression
should follow regimens in Table 3 and be based on in vitro
sensitivities, allergies, and intolerances (B-III). Chronic sup-
pression after ﬂuoroquinolone treatment of gram-negative
bacilli was not unanimously recommended (D. L., W. Z.).
Clinical and laboratory monitoring for efﬁcacy and toxicity is
advisable. Similar considerations regarding hazards and effec-
tiveness apply to those above.
Evidence Summary
There are 2 ways a 1-stage exchange can be performed. One
involves purposefully planning to do a 1-stage exchange,
identifying the pathogen preoperatively followed by 4–6
weeks of pathogen-directed intravenous or highly bioavail-
able oral antimicrobial therapy following the exchange pro-
cedure, with or without the use of chronic oral antimicrobial
suppression (Table 2) [14, 101]. A second method, a 1-stage
exchange, is inadvertently due to the fact that a revision
surgery performed for presumed aseptic loosening occurs,
and after surgery a diagnosis of PJI is conﬁrmed by multiple
positive cultures yielding the same organism [13, 14, 175].
This strategy is reported to have a success rate of 80%–
100%. A bioﬁlm active agent for susceptible staphylococcal
infections can be used with a regimen similar to THA infec-
tion treated with debridement and retention, although there
are no speciﬁc clinical data to support rifampin combina-
tions in this setting. Other retrospective studies have used
chronic oral suppression with success [175]. Most members
of the panel supported the use of chronic oral suppression
to prevent relapse of infection (Table 3). The decision to
offer chronic suppressive therapy must take into account the
individual circumstances of the patient including the ability
to use rifampin, the potential for progressive implant loosen-
ing and loss of bone stock, and the hazards of prolonged
antibiotic therapy; it is therefore generally reserved for pa-
tients who are unsuitable for, or refuse, further exchange re-
vision, excision arthroplasty, or amputation. Rifampin alone
and linezolid should not be used for indeﬁnite chronic sup-
pression. Rifampin combination therapy is also not generally
recommended, although 1 member of the panel uses rifam-
pin combination therapy for chronic suppression in selected
situations (A. R. B.) [62].
An approach described by French investigators involves
pretreating patients with up to 6 months of a rifampin-con-
taining oral regimen prior to a 1-stage exchange [66, 71]. This
approach has the possible disadvantage of the patient having a
potentially painful loose prosthesis while having medical
therapy.
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VI. What is the medical treatment for a patient with PJI
following amputation?
37. Pathogen-speciﬁc antimicrobial therapy should be given
until 24–48 hours after amputation assuming all infected bone
and soft tissue has been surgically amputated and there is no
concomitant sepsis syndrome or bacteremia. If sepsis syn-
drome or bacteremia are present, treatment duration is to be
according to recommendations for these syndromes (C-III).
38. Four to 6 weeks of pathogen-speciﬁc intravenous or
highly bioavailable oral antimicrobial therapy is recommended
if, despite surgery, there is residual infected bone and soft
tissue (ie, hip disarticulation for THA infection, long-stem
TKA prosthesis where the prosthesis extended above the level
of amputation; Table 2; C-III).
39. Monitoring of outpatient intravenous antimicrobial
therapy should follow published guidelines (A-II) [6].
Evidence Summary
Data for these recommendations are based on the expert
opinion of the investigators and extrapolated data from data for
staged exchange. Pathogen-speciﬁc antimicrobial therapy follow-
ing amputation should be given until 24–48 hours assuming all
infected bone and soft tissue have been surgically removed and
there is no concomitant sepsis syndrome or bacteremia. If sepsis
syndrome or bacteremia is present, treatment duration should
be according to recommendations for these syndromes. Four to
6 weeks of pathogen-speciﬁc intravenous or highly bioavailable
oral antimicrobial therapy is recommended if there is residual
infected bone (ie, hip disarticulation for THA infection, long-
stem TKA prosthesis where the prosthesis extended above the
level of amputation) as would be recommended for chronic os-
teomyelitis. Monitoring of outpatient intravenous antimicrobial
therapy should follow published guidelines [6].
RESEARCH GAPS
The initial step in developing a rational clinical research
agenda is the identiﬁcation of gaps in information. The
process of guideline development, as practiced by IDSA,
serves as a natural means by which such gaps are identiﬁed.
Thus, the guidelines identify important clinical questions and
identify the quality of evidence supporting those recommen-
dations. Clinical questions identiﬁed by guideline authors and
members of the IDSA Research Committee and SPGC that
could inform a research agenda for the diagnosis and manage-
ment of PJI are included below.
Epidemiology
What is the incidence rate of PJI in patients who undergo dif-
ferent types of joint arthroplasty and what are the risk factors
that predispose patients to PJI? What type of database and
epidemiologic information would be useful for future studies
to improve the diagnosis and management of PJI (eg, national
registry)?
Diagnostics
Can rapid methodologies, such as polymerase chain reaction,
be used to optimally identify pathogens causing PJI? What is
the role of prosthesis sonication and beadmill processing in
the diagnosis of PJI? Is there an optimal incubation time to
recover bioﬁlm organisms? What is the role of inﬂammatory
biomarkers in synovial ﬂuid and serum in the diagnosis of
PJI? What are the best molecular, radiographic, and culturing
methods for diagnosing PJI?
Management
What are the optimal and most cost-effective algorithms of
surgical and medical treatment strategies for the management
of PJI? What is the efﬁcacy of oral vs parenteral therapy, or
oral step-down therapy as an alternative to prolonged paren-
teral therapy? What is the efﬁcacy of rifampin combination
therapy for staphylococcal PJI? What are alternatives to vanco-
mycin for the management of infection with MRSA or coagu-
lase-negative Staphylococcus? What is the role of chronic
suppression, where is it indicated, and how much is adequate?
Which agents are appropriate for suppression?
When is it appropriate to perform 1-stage vs 2-stage reim-
plantation? When is the appropriate time to reimplant when
using a 2-stage exchange? What factors, including demograph-
ics, microbiology, serum inﬂammatory markers, and imaging
studies, are useful in predicting the outcome of PJI?
Prevention
What is the role of antibiotic prophylaxis in patients undergo-
ing dental procedures or invasive (gastrointestinal, genitouri-
nary) procedures? What is the role of S. aureus screening and
decolonization with mupirocin and/or chlorhexidine bathing
prior to surgery? How does higher oxygen therapy adminis-
tered in the operating room impact the prevention of PJI?
What roles do operative markers such as hypothermia and
blood transfusion play in preventing PJI?
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